Atticus Analysis

2.2K posts

Atticus Analysis banner
Atticus Analysis

Atticus Analysis

@atticusanalysis

Always learning more about investing/trading. Substack: https://t.co/o20qH8nxrm Discord: https://t.co/Ajn2xBZfL0 Not investment advice

Beigetreten Eylül 2021
527 Folgt360 Follower
Atticus Analysis
Atticus Analysis@atticusanalysis·
@semodough Can you link me to the $BBIO presentation? Having a hard time finding it on the ACC site.
English
0
0
0
195
dough
dough@semodough·
$CYTK $BBIO American College of Cardiology 2026 Conference will be held on March 28-30th in New Orleans. Conference abstract policy (Link) notes that "Full text of the abstracts and cases will be viewable in the online/mobile program planner systems beginning Monday, March 16, 2026, at 8 a.m. ET.
Michel Doepke@doepke_michel

$CYTK Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo globenewswire.com/news-release/2…

English
1
2
6
4.5K
Kiefer
Kiefer@kasel90·
@justfactstruth Hey mate, appreciate you being very transparent. I've got some things to share re $FTAI which are hopefully useful. DM me
English
3
0
0
217
Frank
Frank@justfactstruth·
Sold my $PBF for 60%+ return...added more $NRG $FTAI
Frank@justfactstruth

$PBF Why PBF PBF is already the largest US importer of Venezuelan crude, handling about 28% of recent volumes If US imports scale back and well above the pre-2019 levels (~800,000 bpd from today's ~135,000 bpd) this will dramatically improve margins and volumes Carlos Slim, Latin America's richest man owns 25% of the common Slim attended Trump's 2025 inauguration and has consul re: Mexico and LatAm advice for his second term. Trump TruthSocial post- “We met for a "lovely dinner" at Mar-a-Lago and Slim is "a great guy” PBF as of October 25 was doing 40K bpd of Venny crude but could ramp to as much as 180-200k bpd PBF's average revenue per barrel in Q3 2025 was ~$95 (revenue of $7.65B on 80.12 million barrels). Applying this to the incremental volume yields an estimated revenue increase of ~$5.55B annually, assuming similar product yields and pricing. This could be higher (up to $5.8B-$6.2B) if Venezuelan crude's lower cost allows for optimized mixes amid diesel demand. From the data, PBF's Q3 2025 gross refining margin (excluding special items) was $9.00 per barrel on throughput of approximately 871,000 bpd (80.12 million barrels for the quarter). Scaling up Venezuelan crude imports from 40k bpd to 200k bpd represents an incremental 160,000 bpd, or ~58.4 million barrels annually. Factoring Venezuelan potential crude's discount ($10-15/bbl cheaper than alternatives, leading to 20-30% margin uplift from efficiencies and lower input costs), adjusted EBITDA could rise by $700M-$1.05B (at $12-$18 per barrel effective margin, assuming 90-95% utilization vs. current 85%).

English
4
1
15
4.8K
Biotech2k
Biotech2k@Biotech2k1·
$PTGX is about $20 over valued. Either JNJ is a grater fool than me soon, or I need to sell this one soon.
English
2
0
4
2.5K
Joel
Joel@growthrapidly·
Honest question: What’s one sector you would never buy stocks in? For me, it’s biotech.
English
172
3
141
22.2K
Carson
Carson@CarsonTalkMoney·
There are so many opportunities in this market, but the top three IMO are 1) $SOFI 2) $GRAB 3) $ZETA If you had to say your top three opportunities, what would they be?
English
24
3
98
8.9K
Atticus Analysis
Atticus Analysis@atticusanalysis·
What is going on with $WGS??
English
0
0
1
83
Atticus Analysis
Atticus Analysis@atticusanalysis·
@iamklausenburg I would have no interest in a woman who is average IQ or below and no interest in a woman who is submissive.
English
0
0
0
6
Atticus Analysis
Atticus Analysis@atticusanalysis·
$FTAI Earnings call - did management just say they have multiple customers who want to buy their ENTIRE CAPACITY of 100 power turbines in 2027? Reminder this is a minimum of 2.5b of revenue upfront, plus servicing contracts.
English
0
0
1
126
Atticus Analysis
Atticus Analysis@atticusanalysis·
@Biotech2k1 I'm interested in learning more about $LIFE but there is so little info. Did you listen to the call? it seemed a bit light on the details IMO.
English
1
0
1
44
Biotech2k
Biotech2k@Biotech2k1·
My Honest Ranks so far: Neobanks: 1. $SOFI 2. $CHYM BNPL: 1. $AFRM 2. $KLAR 3. $SEZL Insurtech: 1. $LIFE 2. $LMND 3. $ROOT Payments: 1. $FOUR 2. $TOST Credit Tech: 1. $UPST 2. $PGY
English
2
0
14
2.4K
Atticus Analysis
Atticus Analysis@atticusanalysis·
@PersimmonTI Number two holding for me. How do you deal with the emotionally frustrating price action on after such a stellar call?
English
0
0
0
104
Atticus Analysis
Atticus Analysis@atticusanalysis·
$BBIO what a call. CEO is amazing. Hard to go into all the details but just listening to him you know this company is a winner. On and he's projecting top 20-30 bio firm globally in just a few years?? Yes he said that.
English
0
0
2
695
Atticus Analysis
Atticus Analysis@atticusanalysis·
@taeyoon43334145 $BBIO $108.1 million of U.S. Attruby net product revenue in q3, $146.0 million in Q4? Pretty decent if you ask me.
English
0
0
1
388
American
American@taeyoon43334145·
$bbio. Q over Q revenue is very meh. Hardly impressive. Love their pipeline and progress. Prob isnt going anywhere soon as far as share prices
English
1
0
0
420
Atticus Analysis
Atticus Analysis@atticusanalysis·
@DwightS2025 @semodough $BBIO just did a convertible note thing like a month ago. Its also going to be profitable next year. Why would they need an equity raise?
English
0
0
1
217
Dwight Shrewd
Dwight Shrewd@DwightS2025·
@atticusanalysis @semodough Totally disagree. Analysts praise it because the want the upcoming equity raise and the KOL’s they are hosting are paid BBIO consultants. If you run a survey with a broader N, my view is the majority amongst clinicians. Docs don’t mess around with kid’s safety
English
1
0
0
88
dough
dough@semodough·
$BBIO BofA new note PT$97 BridgeBio’s positive infigratinib data is a milestone for achondroplasia. Indeed, given clear evidence of efficacy and (esp) safety of an MoA directly targeting the underlying mutation – and with it, potential to extend the depth/breadth of benefit (see our PROPEL3 takes) – in a convenient oral form, there’s every reason to think the TKI will be practice-changing, with opportunities to expand the market as well.
dough@semodough

$BBIO Cowen Achon KOL Call: Infi Likely To Become Standard Of Care Reaching Up To 80% Share KOL expects ~50% switching from injectables to orals like infi, with a steady‑state of ~80% oral share, and 30%+ population penetration upside from activating untreated patients avoiding shots. $BMRN

English
2
2
13
5K
Atticus Analysis
Atticus Analysis@atticusanalysis·
@DwightS2025 @semodough There is a chance you may be correct but I think even you would admit your perspective is a minority view. The broader community does not share your perspective - if it did, analysts wouldn't have praised the drug - so I don't think your concern is what's moving the stock now.
English
1
0
0
83
Dwight Shrewd
Dwight Shrewd@DwightS2025·
@atticusanalysis @semodough Because the next Infi update will likely be first case of ocular or neurtox. Only the BBIO paid KOL’s project uptake. The rest are spooked by safety.
English
1
0
0
79
𝕃𝕦𝕜𝕖 𝔹𝕠𝕚
$LITM slow and steady now into new Company, starting next Monday. My prediction is: Closing the week around 4$ Closing the month above 6$
English
1
1
6
912
Valuation Finance
Valuation Finance@baseloadinvest·
$ALHC That is an excellent, fast-growing company. However, right now, it's facing headwinds due to AI's software threat and the market is assessing the company's tech-enabled AVA model. Some in the space are moving toward 52-week lows. I would not go in now. But contemplate entry when the fog clears when the moat seems clear and defendable.
Atticus Analysis@atticusanalysis

@baseloadinvest @Market_Kap @CloverHealth I'm very interested in learning more about $ALHC. What is the best deep dive etc? Or are you an expert on the name?

English
1
0
0
92
Valuation Finance
Valuation Finance@baseloadinvest·
@Market_Kap @CloverHealth If you think the health insurance business models is broken, why don't you go with the market leader in tech-enabled, value-based care: $ALHC?
English
1
0
0
49
MarketKap
MarketKap@Market_Kap·
$CLOV @CloverHealth Everyone is underestimating what a massive challenge these regulatory headwinds will be for dinosaur insurers. Their business models are fundamentally broken. $MOH , $UNH , $HUM and others will need a quick-to-implement system for this unforgiving shift toward Value Based Care, or risk hemmoraging quarter after quarter, year after year. @counterparthlth Counterpart Health has their solution. 🚀
MarketKap tweet media
English
3
3
40
3.4K
Simon L
Simon L@SnupSnus·
@atticusanalysis @Craigster771 I mean if it's like infringing matter found ot something like that but the technicalities of this and that are wildely different
English
1
0
0
65
Simon L
Simon L@SnupSnus·
That's quite a nasty suprise to come home too ( $BBIO) bit how much read-through onnusbpatents do EU patents really have (mRNA $ABUS $ROIV same issue)
English
1
0
0
1.2K